Artia Global Partners LP purchased a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 65,122 shares of the medical research company's stock, valued at approximately $13,803,000. Quest Diagnostics comprises approximately 2.5% of Artia Global Partners LP's holdings, making the stock its 12th largest holding. Artia Global Partners LP owned 0.06% of Quest Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Key Financial Inc boosted its position in shares of Quest Diagnostics by 1,728.6% during the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company's stock valued at $25,000 after purchasing an additional 121 shares in the last quarter. Ancora Advisors LLC acquired a new stake in Quest Diagnostics during the 2nd quarter valued at $29,000. Quattro Advisors LLC acquired a new stake in Quest Diagnostics during the 4th quarter valued at $25,000. Sittner & Nelson LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter valued at $29,000. Finally, DV Equities LLC purchased a new stake in shares of Quest Diagnostics in the fourth quarter valued at $27,000. Institutional investors own 88.06% of the company's stock.
Quest Diagnostics Price Performance
NYSE:DGX opened at $244.78 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.59 and a quick ratio of 1.46. The company has a fifty day moving average price of $222.01 and a 200 day moving average price of $206.46. Quest Diagnostics Incorporated has a one year low of $171.18 and a one year high of $246.00. The stock has a market cap of $27.02 billion, a P/E ratio of 25.99, a PEG ratio of 2.25 and a beta of 0.56.
Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.82 by $0.30. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $2.97 billion. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.Quest Diagnostics's revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.62 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. Analysts anticipate that Quest Diagnostics Incorporated will post 11.15 earnings per share for the current year.
Quest Diagnostics Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 21st. Stockholders of record on Tuesday, October 6th will be paid a $0.86 dividend. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Tuesday, October 6th. Quest Diagnostics's dividend payout ratio (DPR) is 36.52%.
Insiders Place Their Bets
In related news, SVP Mark E. Delaney sold 1,600 shares of the business's stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $235.18, for a total transaction of $376,288.00. Following the completion of the sale, the senior vice president directly owned 10,335 shares of the company's stock, valued at $2,430,585.30. The trade was a 13.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares in the company, valued at $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 19,747 shares of company stock valued at $3,947,088. 0.88% of the stock is currently owned by insiders.
Analyst Ratings Changes
Several brokerages recently issued reports on DGX. Mizuho increased their price objective on Quest Diagnostics from $235.00 to $260.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. UBS Group lifted their target price on Quest Diagnostics from $220.00 to $232.00 and gave the company a "neutral" rating in a research note on Friday, July 24th. Barclays raised their price target on shares of Quest Diagnostics from $230.00 to $250.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Wall Street Zen raised shares of Quest Diagnostics from a "hold" rating to a "buy" rating in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $245.00 price target on shares of Quest Diagnostics in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Quest Diagnostics has a consensus rating of "Moderate Buy" and an average target price of $235.31.
Check Out Our Latest Analysis on Quest Diagnostics
Quest Diagnostics Company Profile
(
Free Report)
Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.
Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Quest Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.
While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
